Sign in

Trial result ·

Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.

Written based on 1 research study on PubMed, searched on 5 Nov 2026.

What was studied

This study looked at a new antibiotic called HRS-8427. It is being tested for germ infections of the urine tract and lungs. Many people with these infections also have weak kidneys. The kidneys clear much of this drug from the body. This was an early, phase 1 study at several sites. People got single doses of 1,000 mg of the drug. It included 21 people with mild to severe kidney damage, not on dialysis. It also had people with normal kidneys. People on dialysis for kidney failure got doses both with and without dialysis.

What they found

Drug levels in the blood rose as kidney damage got worse. Levels were about 1.2 times higher with mild damage than in healthy people. They were about 1.4 times higher with moderate damage. They were 2.0 times higher with severe damage. In kidney failure without dialysis, levels were about 2.0 times higher. In people on dialysis, a dose given before dialysis gave lower drug levels. Those levels were lower than when the dose came after dialysis. Side effects were mostly mild. Kidney damage did not seem to raise the risk of side effects.

What it means for patients

Weak kidneys seem to keep more of this drug in the blood. Dialysis seems to take some of the drug out of the blood. Kidney damage did not seem to bring more side effects. The timing of a dose around dialysis may change drug levels.

Why it is not certain yet

This was an early study. Only 21 people with kidney damage not on dialysis took part. The study used single doses only. It was an open study, so everyone knew what they got. The abstract does not say how doses should change for weak kidneys. This study did not test whether the drug treats infections.

The registered trial

The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.

Source

Effects of renal impairment and hemodialysis on the pharmacokinetics and safety of HRS-8427, a siderophore cephalosporin for Gram-negative bacterial infections.

PubMed · PMID 41528248

We restate facts from the source record in our own words. The original wording belongs to its publisher.

This page is not medical advice. Talk to your doctor about your own care.

Back to Chronic kidney disease publications